Tax
The QSBS $75M Gross Assets Test: Why Your Post-Money Doesn't Count and Your Capitalized R&D Does
The QSBS $75M gross assets test measures tax basis, not valuation. What counts toward it, and how Section 174A changed the math for R&D-heavy startups.
By 409.AI Team - 2026-09-14
# The QSBS $75M Gross Assets Test: Why Your Post-Money Doesn't Count and Your Capitalized R&D Does
Two founders ask the same question about QSBS eligibility, and both get it wrong in opposite directions.
The first closed a Series B at a $180 million post-money and assumes the exclusion is long gone. The second has raised $52 million in total, keeps most of it in T-bills, and assumes the company is comfortably under the line. Neither of those numbers is the one Section 1202 reads.
The size test that decides whether a round's shares carry the qualified small business stock exclusion has nothing to do with what investors think your company is worth. It measures the tax basis of what the company owns. That gap between valuation and basis is where most cap tables quietly lose an exclusion worth up to $15 million per shareholder, and it usually surfaces years later, during exit diligence, when nothing can be done about it.
What the statute actually measures
Section 1202(d)(1) sets two conditions, and both have to hold. The corporation's aggregate gross assets must have been at or below the threshold [at all times](https://www.law.cornell.edu/uscode/text/26/1202) "on or after the date of the enactment of the Revenue Reconciliation Act of 1993 and before the issuance," and they must still be at or below it "immediately after the issuance (determined by taking into account amounts received in the issuance)."
Then the definition, in 1202(d)(2): aggregate gross assets means "the amount of cash and the aggregate adjusted bases of other property held by the corporation."
Read that twice, because four things follow from it.
It's tax basis, not value. Not your 409A, not your post-money, not GAAP book value. The goodwill you've built, the brand, the model weights your team trained, the codebase: self-created intangibles generally carry no tax basis, so they contribute nothing. A company can be worth $400 million and sit at $30 million of gross assets.
It's gross, not net. Liabilities don't offset anything. Draw $25 million of venture debt and park it in the bank, and you've just added $25 million to the test while adding nothing to equity value. Same for a convertible note before it converts.
Cash raised is the engine. Money that comes in the door counts as cash at 100 cents. Spend it on salaries and rent and it leaves the balance sheet. Spend it on something you capitalize and it stays, in a different costume, at basis.
The history matters, not just today. That phrase "at all times ... before the issuance" makes this a high-water-mark test across the company's entire life. Touch the ceiling once and every subsequent issuance fails, even if assets fall back later. Shares issued before the crossing keep their status permanently, which is why early employees at very large companies sometimes still hold genuine QSBS.
Two mechanical points round it out. Subsidiaries count: under 1202(d)(3), a parent and its more-than-50%-owned subsidiaries are treated as one corporation. And the threshold depends on when the stock was issued. It's $75 million for stock issued after July 4, 2025, and $50 million for anything earlier, a change we walked through in [what the One Big Beautiful Bill Act did to Section 1202](https://409.ai/articles/qsbs-one-big-beautiful-bill-act-section-1202-changes). That $75 million figure [starts adjusting for inflation in 2027](https://409.ai/articles/qsbs-75-million-ceiling-inflation-indexing-2027).
There's one place where value does drive the test rather than basis. Under 1202(d)(2)(B), property contributed to the corporation is treated as having a basis equal to its fair market value at the time of contribution. That rule is what makes an LLC conversion so dangerous, and it's the reason [the conversion-day valuation decides what you can exclude](https://409.ai/articles/llc-to-c-corp-conversion-qsbs-valuation-section-1202).
The part almost nobody modeled: capitalized R&D
For tax years 2022 through 2024, the Tax Cuts and Jobs Act version of Section 174 did something startups felt immediately in their cash taxes and almost never connected to QSBS. Research and experimental expenditures could no longer be deducted when incurred. Domestic R&E had to be amortized ratably over five years, and foreign R&E over fifteen, in each case [beginning with the midpoint of the tax year](https://www.law.cornell.edu/uscode/text/26/174) the money was spent. Software development costs were swept in.
Here's the consequence for the size test. When an R&D-heavy startup paid engineers under that regime, the cash left the bank but an amortizable intangible with real tax basis took its place. The dollar didn't disappear from aggregate gross assets. It changed line items.
So the companies most likely to trip the gross assets ceiling were exactly the ones the exclusion was written for: capital-efficient, engineering-heavy, spending most of their raise on domestic payroll.
A worked example
Meridian Systems incorporated in Delaware in 2021 and raised $67 million across three rounds. Its domestic R&E spend was $6 million in 2022, $12 million in 2023, and $18 million in 2024. Under the five-year schedule with amortization starting at each year's midpoint, roughly 10% of a year's spend amortizes in year one and 20% each year after.
| Spend year | Amount | Amortized through 2024 | Unamortized basis | |---|---|---|---| | 2022 | $6M | $3.0M | $3.0M | | 2023 | $12M | $3.6M | $8.4M | | 2024 | $18M | $1.8M | $16.2M | | Total | $36M | $8.4M | $27.6M |
Meridian carries $27.6 million of unamortized Section 174 basis into 2025. Say that by mid-2026 it holds $18 million in cash and $5 million of equipment and other assets at adjusted basis. Aggregate gross assets: $50.6 million. Still under the ceiling, with $24.4 million of headroom.
Now it signs a $30 million Series C. Immediately after the issuance, gross assets are $80.6 million. The test fails, and not one share of that Series C is QSBS. The new investors lose the exclusion. So does anyone exercising an option from that point on, because each issuance is tested on its own date, and Meridian has now crossed a line it can't uncross.
Strip the $27.6 million of R&D basis off the balance sheet and the same round lands at $53 million. Comfortably qualified. Nothing about the business changed. The difference is entirely an accounting method.
What Section 174A changed
The One Big Beautiful Bill Act added Section 174A, which restores current deductibility for domestic research and experimental expenditures for tax years beginning after December 31, 2024. Section 174 now governs foreign research, still at fifteen years. Grant Thornton's summary of the provision is a [clean read on the mechanics and elections](https://www.grantthornton.com/insights/alerts/tax/2025/insights/full-expensing-of-domestic-research).
Two effects matter for the size test.
Going forward, domestic R&D stops building basis. Every dollar you spend on US engineering now reduces gross assets instead of relocating them, which gives an R&D-heavy company more room under $75 million than the old rules ever did.
Looking back, the stranded 2022 through 2024 balances can come off. OBBBA lets taxpayers deduct remaining unamortized domestic R&E either entirely in the first tax year beginning after December 31, 2024, or ratably across that year and the next. The IRS laid out the elections and accounting method changes in [Revenue Procedure 2025-28](https://www.irs.gov/pub/irs-drop/rp-25-28.pdf). Smaller companies meeting the Section 448(c) gross receipts test, $31 million of average annual gross receipts, had a separate election to apply 174A retroactively all the way to tax years beginning after December 31, 2021. That one had a hard deadline of the earlier of July 6, 2026 or the refund claim deadline, and it has passed. WilmerHale's analysis flagged the QSBS angle directly, noting that [capitalized R&D may have kept companies from clearing the old $50 million test](https://www.wilmerhale.com/en/insights/publications/20260414-obbba-highlights-qualified-small-business-stock-and-rd-expense-deductions) in the first place.
If your 2025 return is still on extension, the choice between deducting those balances now or spreading them is live, and it's no longer only a cash-tax question. It moves the number that decides whether your next round is QSBS. Your tax advisor should be running both versions with the closing balance sheet in front of them.
One caveat worth saying plainly: if your engineering team sits in Toronto, Warsaw, or Bangalore, none of that relief reaches those costs. Foreign R&E still capitalizes over fifteen years and still builds basis. A distributed company can watch its US spend stop counting while its offshore spend keeps piling onto the test.
What clearing the size test doesn't buy you
Gross assets is one gate of several, and it's the only one that runs on tax basis. The company still has to be a domestic C corporation running a qualified trade or business, which rules out more startups than founders expect once you read [the consulting and services tests](https://409.ai/articles/qsbs-qualified-trade-or-business-consulting-test-section-1202). It still has to keep 80% of assets in active use. Holding periods still govern how much gain comes out, now on a tiered 50/75/100% ramp at three, four, and five years for post-enactment stock. And a routine-looking buyback can wipe out an entire year of issuances under [the redemption rules](https://409.ai/articles/qsbs-redemption-rules-stock-buybacks-section-1202).
It's also worth separating this from your 409A. They're different measurements answering different questions, in the same way [a 409A and fair market value aren't interchangeable terms](https://409.ai/articles/409a-valuation-vs-fair-market-value). Your 409A sets a strike price. The gross assets test reads a tax balance sheet. The only overlap is the contributed-property rule above, where a defensible valuation is exactly what you need, and where a [QSBS attestation letter](https://409.ai/products/qsbs) is what puts the conclusion in writing for investors and buyers. If you hold SAFEs, they raise a separate question about [when the Section 1202 clock even starts](https://409.ai/articles/safes-qsbs-holding-period-conversion-section-1202).
The takeaway
Almost every QSBS test is retrospective. You find out whether the company was a qualified trade or business, or whether a redemption blew up an issuance, when a buyer's counsel asks during diligence and the answer is already fixed.
The gross assets test is different. It's the one input you can compute to the dollar before you sign anything, and, right now, the one you can still move. Pull the tax balance sheet as of the expected closing date, add the new money, and see where it lands. If the total is anywhere within $10 million of $75 million, the size of the round has become a tax decision for every investor and employee in it, and an unamortized R&D balance you've been carrying since 2022 may be the cheapest thing on the list to fix.
Meridian's Series C investors lost an exclusion worth up to $15 million each because a five-year amortization schedule was still running. That's an expensive way to find out which number the statute reads.